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INTRODUCTION
The decision between self-renewal and lineage commitment of hematopoietic stem cells (HSC) is mainly regulated by extracellular signals from the hematopoietic microenvironment that induce differential expression of key transcription factors.
Aberrant expression or function of these factors contributes significantly to leukemogenesis 1, 2 . Clonal expansion of immature hematopoietic cells, due to alterations of differentiation-inducing transcription factors, is the hallmark of acute myeloid leukemia (AML) 2, 3 . MN1, meningioma 1, was identified in a patient with meningioma, as a target of a chromosome translocation t(4;22) 4, 5 . Subsequent studies showed that MN1 is also involved in AML either as a partner of a recurrent translocation t(12;22)(p12;q12), encoding an MN1-TEL fusion protein 6 , or as an overexpressed gene in 2 subsets of AML specified by the presence of inv(16) or by overexpression of ecotropic viral integration site 1 (EVI-1) 7, 8 . Our recent studies showed that ectopic expression of MN1 or MN1-TEL in hematopoietic cells causes myeloid disease in mice 9, 10 . Moreover, MN1 cooperates with CBFβ-MYH11, the product of inv(16), in a murine model of inv(16)-AML and accelerates leukemogenesis 9 . MN1 also prevents granulocytic differentiation and abrogates all-trans retinoic acid (ATRA)-mediated growth inhibition in primary mouse hematopoietic cells 11 . In addition, MN1
overexpression eliminated the beneficial effects of the addition of ATRA to the maintenance chemotherapy of non-acute promyelocytic leukemia (APL)-AML patients, whereas in AML patients with low MN1 expression, ATRA administration increased survival 11 .
The transcription factor CEBPA, CCAAT enhancer binding protein-α (C/EBPα), plays an essential, non-redundant role in the decision of HSC to selfrenew or differentiate into a myeloid direction 12 and it is activated by ATRA 13 . CEBPA regulates expression of several myeloid-specific genes such as granulocyte-colony stimulating factor receptor (G-CSFR), monocyte-colony stimulating factor receptor (M-CSFR) 14 and miR-223 13 via direct binding to sites in their promoters. Cebpa knockout mice showed a profound defect in the generation of granulocyte-monocyte progenitors (GMP) from common myeloid progenitors (CMP), resulting in a lack of granulocytes and impaired macrophage development 12, 14, 15 . Concordantly, absence
of Cebpa enhances the repopulating and self-renewal capacity of hematopoietic
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Although MN1 is a novel player in AML pathophysiology, the molecular 4326321E, 4310884E, Hs00977137-m1, Hs00269972-s1, Hs99999142-m1, Hs00167918-m1, Hs00911250-m1, Hs00189032-m1, respectively). The MN1 primer and probe sets were as described 9 . Expression levels were obtained by using the standard curve method (after normalization with a house keeping gene). The
MATERIALS AND METHODS

Plasmids and viral packaging
TaqMan microRNA assay kit for RNU6B (used as endogenous control and normalizer) and miR-223 were from Applied Biosystems (Foster City, CA, USA; part no: 4373381 and 4373075, respectively). RT-PCR reactions were performed according to the manufacturer's instructions.
FACS analysis
Cells were washed and taken up in blocking solution (PBS containing 5% fetal bovine serum, 2mM sodium azide and 0.1mg/ml human gamma globulin) for 30 minutes on ice. Biotec (Auburn, CA, USA) and anti-mouse antibodies (Mac1-PE, Gr1-APC, Sca1-PerCP-Cy5-5) were from BD Biosciences (San Jose, CA, USA), except for ckit-APCAlexa750 (eBiosciences, San Diego, CA, USA). In some experiments, cells engineered to express either GFP or YFP or both were counterstained with PI to mark dead cells and were analyzed using FACS Vantage-SE-DiVa cell sorters (BD Biosciences, San Jose, CA); subpopulations of viable cells expressing these fluorescent proteins were collected by FACS. Cell cycle and apoptosis assays were performed using FACS as described 24 . Immunocytochemistry of HL60-MN1 and U937-MN1 cells using anti-MN1 antibody was performed as described 9 .
Western Blots and immunocytochemistry
Mouse bone marrow culture
BM cells were isolated and cultured as described by Wang D et. al. 25 with additional lineage depletion after initial BM isolation. Methylcellulose assays were performed by plating FACS-sorted, engineered cells into MethoCult GF M3534 (StemCell Technologies, Vancouver, BC, Canada) 26 .
Statistical Analysis
Unpaired t-Test analysis (two-tailed) was performed using the GraphPad Prism version 4.0c for Mac (GraphPad Software Inc., San Diego, CA, USA.
www.graphpad.com). Figure 3C ), which was accompanied by increased expression of the differentiation marker CD11b ( Figure 3D) . In contrast, G-CSFR expression in MN1-cells was maintained at the level of that in untreated-mock Figure 3C ) and CD11b expression was 2.8 fold lower in MN1 cells treated for 24 hour compared to treated mock cells ( Figure 3D ).
RESULTS
MN1 overexpression inhibits ATRA or vit-D3 induced myeloid differentiation of AML cell lines
Upregulation of miR-223, another direct target of CEBPA that is critical for granulocytic differentiation 13 , was also partially blocked in ATRA treated U937-MN1 cells ( Figure 3E ).
We also analyzed the expression of RARβ -an ATRA-activated RAR/RXR target-in the same RNA samples in Figure 3C . As expected, untreated U937-mock cells did not express RARβ whereas mock and MN1-cells showed similar levels of Figure 4H ).
CEBPA restores myeloid differentiation of MN1-expressing mouse HSPC and inhibits colony formation
To study the differentiation and proliferation capacity of primary mouse HSPC Figure 2G and 2H, respectively). We believe that this activity is cell type and context dependent, given that in human osteoblast 29 and epithelial cell lines 30 increased MN1 expression is correlated with growth arrest.
Although we do not know how MN1 induces growth of hematopoietic cells, we believe that direct or indirect repression of CEBPA and its target genes (microarray analysis, data not shown and Figure 3A ), all critical regulators of selfrenewal/proliferation and lineage commitment 12, 16 , is one of the important consequences of MN1 over expression. Our findings raise the possibility that MN1 might be involved in self renewal/myeloid commitment decisions of primitive hematopoietic cells, which is further supported by the following observations: 1)
Endogenous MN1 expression is downregulated in primary or in vitro differentiated human monocytes and granulocytes (Figure 2A and 2B ). Enforced expression of MN1 fulfills these criteria by deregulating both activities 9, 11 ( Figure 1C, 1D, 2C , 2E, 2F, 5E and 5F). Given that CEBPA is downregulated in CD34-MN1 cells ( Figure 3A) , and is indispensable for granulocytic and monocytic maturation 15 Currently we do not know how MN1 exerts its effect on CEBPA expression and activity but our data clearly indicate that reintroduction of CEBPA is sufficient to limit the effect of MN1 on proliferation and myeloid differentiation in vitro. This is similar to CEBPA's effect on human wild type CD34 + and AML-CD34 + cells 17 . Based on our results, it is tempting to speculate that in hematopoietic cells, MN1 represses CEBPA expression via factors required for its transcription, or perhaps via epigenetic modifications of the CEBPA promoter region. CEBPA exerts its function via direct binding to promoter/enhancer regions of its target genes as well as via posttranslational modifications and protein-protein interactions 28, 36 . Because MN1
can bind the transcriptional coactivator p300 35 , we analyzed if recruitment of MN1 to the CEBPA/p300 protein complex would inhibit CEBPA's transcriptional activity in U937-MN1-cells but we were unable to detect any interaction between CEBPA and
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